Sumitomo Pharma Co Ltd 2023 Integrated Report
The report details Sumitomo Pharma Group's strategic transition under the Mid-term Business Plan 2027 to address the loss of exclusivity for LATUDA® and drive renewed growth through three core products. The company focuses on expanding its pipelines in psychiatry, neurology, oncology, and regenerative medicine, alongside organizational restructuring in North America. Additionally, Sumitomo Pharma enhanced its environmental commitments by committing to the Science Based Targets initiative and setting a target to reduce Scope 1 and 2 emissions by 42% by fiscal 2030.
Company: Sumitomo Pharma Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2023
Type: Integrated Report
Pages: 114
Back to company
Sumitomo Pharma Co Ltd
Integrated Report
The report details Sumitomo Pharma Group's strategic transition under the Mid-term Business Plan 2027 to address the loss of exclusivity for LATUDA® and drive renewed growth through three core products. The company focuses on expanding its pipelines in psychiatry, neurology, oncology, and regenerative medicine, alongside organizational restructuring in North America. Additionally, Sumitomo Pharma enhanced its environmental commitments by committing to the Science Based Targets initiative and setting a target to reduce Scope 1 and 2 emissions by 42% by fiscal 2030.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2022
Published
Oct 1, 2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Women on Board
Women in Management
Net Zero Target
Employees